CY1869A - Method of preventing or limiting reperfusion damage - Google Patents

Method of preventing or limiting reperfusion damage

Info

Publication number
CY1869A
CY1869A CY186996A CY186996A CY1869A CY 1869 A CY1869 A CY 1869A CY 186996 A CY186996 A CY 186996A CY 186996 A CY186996 A CY 186996A CY 1869 A CY1869 A CY 1869A
Authority
CY
Cyprus
Prior art keywords
preventing
reperfusion damage
compound
limiting reperfusion
limiting
Prior art date
Application number
CY186996A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY1869A publication Critical patent/CY1869A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Protection Of Pipes Against Damage, Friction, And Corrosion (AREA)
  • Dicing (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Suspension Of Electric Lines Or Cables (AREA)
  • Golf Clubs (AREA)
  • Branch Pipes, Bends, And The Like (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Paper (AREA)
  • External Artificial Organs (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY186996A 1989-11-22 1996-04-05 Method of preventing or limiting reperfusion damage CY1869A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44014289A 1989-11-22 1989-11-22
SG118494A SG118494G (en) 1989-11-22 1994-08-20 Method of preventing or limiting reperfusion damage

Publications (1)

Publication Number Publication Date
CY1869A true CY1869A (en) 1996-04-05

Family

ID=26664237

Family Applications (1)

Application Number Title Priority Date Filing Date
CY186996A CY1869A (en) 1989-11-22 1996-04-05 Method of preventing or limiting reperfusion damage

Country Status (22)

Country Link
EP (2) EP0455789B1 (fr)
JP (1) JP2574585B2 (fr)
KR (1) KR0165686B1 (fr)
AT (2) ATE213943T1 (fr)
AU (1) AU632888B2 (fr)
CA (1) CA2044143C (fr)
CY (1) CY1869A (fr)
DE (2) DE69033926T2 (fr)
DK (2) DK0577171T3 (fr)
ES (2) ES2053208T3 (fr)
FI (1) FI109694B (fr)
HK (1) HK115095A (fr)
HU (1) HU215847B (fr)
IE (1) IE65121B1 (fr)
IL (1) IL96390A (fr)
NO (2) NO304519B1 (fr)
NZ (1) NZ236168A (fr)
PT (2) PT95959B (fr)
RU (1) RU2093156C1 (fr)
SG (1) SG118494G (fr)
WO (1) WO1991007967A2 (fr)
ZA (1) ZA909345B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9202266D0 (sv) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel piperazine carboxamides
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
RU2216549C2 (ru) * 1997-11-07 2003-11-20 Дайити Фармасьютикал Ко., Лтд. Пиперазин-циклодекстриновый комплекс и лекарственное средство, содержащее указанный комплекс
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904674D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE0001209D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
PT1395567E (pt) 2001-05-18 2009-03-26 Astrazeneca Ab Derivados de 4(fenil-piperazinil-metil)benzamida e sua utilização para o tratamento da ansiedade da dor ou de distúrbios gastrointestinais
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
WO2005047274A1 (fr) * 2003-11-12 2005-05-26 Dr. Reddy's Laboratories, Inc. Preparation d'escitaloprame
KR101234421B1 (ko) 2004-08-02 2013-02-18 아스트라제네카 아베 디아릴메틸 피페라진 유도체, 이의 제조 방법 및 용도
FR2946340B1 (fr) 2009-06-05 2011-06-24 Galderma Res & Dev Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
KR101900124B1 (ko) 2014-06-25 2018-09-18 전남대학교산학협력단 전복 박리용 조성물
KR101644299B1 (ko) 2014-07-22 2016-08-02 주식회사 엔바이로젠 오미자 및 삼채 추출물을 유효성분으로 포함하는 전복 박리용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
NZ223847A (en) * 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
WO1991007967A3 (fr) 1991-07-11
PT102145B (pt) 2002-06-28
CA2044143A1 (fr) 1991-05-23
ATE213943T1 (de) 2002-03-15
DE69033926D1 (de) 2002-04-11
KR920700644A (ko) 1992-08-10
ZA909345B (en) 1992-08-26
NO311701B1 (no) 2002-01-14
AU6876391A (en) 1991-06-26
FI109694B (fi) 2002-09-30
IL96390A (en) 1995-06-29
HUT58709A (en) 1992-03-30
JP2574585B2 (ja) 1997-01-22
NO912511D0 (no) 1991-06-26
NO304519B1 (no) 1999-01-04
RU2093156C1 (ru) 1997-10-20
SG118494G (en) 1994-11-25
HU9102436D0 (en) 1991-12-30
IL96390A0 (en) 1991-08-16
KR0165686B1 (ko) 1999-01-15
EP0577171B1 (fr) 2002-03-06
ATE102831T1 (de) 1994-04-15
PT95959A (pt) 1991-09-13
CA2044143C (fr) 2002-11-19
DE69033926T2 (de) 2002-10-24
EP0455789A1 (fr) 1991-11-13
WO1991007967A2 (fr) 1991-06-13
EP0577171A3 (en) 1994-06-29
NZ236168A (en) 1993-05-26
IE904209A1 (en) 1991-05-22
IE65121B1 (en) 1995-10-04
DK0455789T3 (da) 1994-04-05
HK115095A (en) 1995-07-21
EP0455789B1 (fr) 1994-03-16
HU215847B (hu) 1999-04-28
NO982078L (no) 1991-08-26
AU632888B2 (en) 1993-01-14
FI913433A0 (fi) 1991-07-16
PT95959B (pt) 1998-08-31
ES2173883T3 (es) 2002-11-01
PT102145A (pt) 1999-10-29
DE69007471D1 (de) 1994-04-21
NO982078D0 (no) 1998-05-07
NO912511L (no) 1991-08-26
ES2053208T3 (es) 1994-07-16
EP0577171A2 (fr) 1994-01-05
DK0577171T3 (da) 2002-06-03
DE69007471T2 (de) 1994-06-23

Similar Documents

Publication Publication Date Title
CY1869A (en) Method of preventing or limiting reperfusion damage
NO932745L (no) Triazolyltiometyltiocefalosporinhydroklorid, dets krystalliske hydrat samt fremgangsmaate for fremstilling
GB2239016B (en) N-tert-butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl)isoquinoline-3-carbo xamide & asparaginyl derivatives thereof
EP0151824A3 (en) N-(4-piperidinyl) bicyclic condesed 2-imidazolamine derivatives
AU4438489A (en) Pharmaceutical compositions containing n-(3,4- dimethoxycinnamoyl)anthranilic acid
NZ236293A (en) 1-(alkyl or alkoxyalkyl)-4-phenyl piperidine-4-carboxylic acid amide derivatives; preparatory processes and pharmaceutical compositions
AU3917189A (en) Antipsychotic 3-piperazinyl benzazole, benzisoxazole and benzisothiazole derivatives
ZA921341B (en) 4-((2-benzothiazolyl)methylamino)-a-(3,4-difluorophenoxy) methyl)-1-piperidineethanol.
ZA897349B (en) (-)-2-((2-(2-aminoethoxy)ethoxy)methyl)-4-(2,3-dichloro-phenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine,process for preparing it and pharmaceutical compositions containing it
DE2960627D1 (en) 2-(n-(2'chloro-4'-methyl-thienyl-3')-n-(cyclopropylmethyl)-amino) imidazoline (2), its acid addition salts, pharmaceutical preparations containing them and process for their preparation
IE43848L (en) Pharmaceutical compositions